COMMUNIQUÉS West-GlobeNewswire

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
10/12/2025
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years. PPF is a rare lung condition, more life-threatening than many forms of cancer, [...]
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
10/12/2025
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce [...]
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC
10/12/2025
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFR TM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor [...]
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
10/12/2025
MediWound Reports New Clinical Data Demonstrating NexoBrid ® ’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid ® removes embedded particles in [...]
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
10/12/2025
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens [...]
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets
10/12/2025
$47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera’s growing pipeline, starting with multiple clinically validated TNF superfamily preclinical programs Biotech veteran [...]
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
10/12/2025
Expanding its Portfolio with American Amnion to Serve the Wound Care Needs of Our Veterans POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company [...]
Microbix Launches New Products to Support H3N2 Flu Testing
10/12/2025
Test-Controls & Reference Materials for Labs & Test-Makers MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, [...]
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
10/12/2025
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population [...]
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
10/12/2025
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile pharma collaboration [...]
Bioxodes lève 5,5 millions d'euros dans le cadre d'une extension de la Série A afin de poursuivre la préparation d’un essai pivot pour son candidat-médicament innovant dans le traitement de l'AVC
10/12/2025
Newton Biocapital entre au capital en tant que nouvel investisseur, importante participation des investisseurs historiques Lancement en 2027 d’un essai pivot de phase 2b portant sur BIOX-101 dans le traitement de l’AVC [...]
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
10/12/2025
Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be commercialized as early as H2 [...]
Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility
10/12/2025
TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the successful [...]
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
10/12/2025
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V [...]
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
10/12/2025
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Terns Announces Pricing of Upsized $650 Million Public Offering
10/12/2025
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten [...]
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
10/12/2025
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
10/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price [...]
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
10/12/2025
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 [...]

Pages